Results: IIM patients had visible tracer uptake in the skeletal muscles of the extremities. The muscular 99m Tc-PYP uptake was significantly higher in upper limbs of patients than the uptake in the same muscle groups in healthy controls (uptake[biceps] Background: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc). Objectives: In this longitudinal study we aimed to identify factors associated with an unfavourable outcome in SSc patients with early PAH (SSc-PAH) from the DETECT cohort. Methods: DETECT enrolled patients with SSc fulfilling the 1980 ACR classification criteria, with a minimal disease duration of 3 years since the first non-Raynaud symptom, and with a lung diffusion capacity for CO (DLCO) <60% of the predicted value. A broad range of clinical and laboratory parameters potentially associated with PAH were assessed, and right heart catheterisation (RHC) was performed in all patients at baseline. Patients diagnosed with PAH were followed up for up to 3 years in centers that agreed for the longitudinal part of the DETECT study, collecting data on survival, World Health Organization (WHO) Functional Class (FC), hospitalization, and PAH-specific treatment. Disease progression was defined as the occurrence of any of the following: WHO-FC worsening, PAH therapy with a drug combination, hospitalization, or death. Associations between baseline variables and disease progression were assessed by univariable logistic regression. Results: Of the 145 SSc patients with PH enrolled in DETECT, 87 patients were diagnosed with PAH, of whom 57 participated in the longitudinal study (median follow-up time 12.6 months, interquartile range 10.7-21.7 months). Among these 57 patients, 33/57 (57.9%) had mild PAH, in WHO FC I or II. During follow-up, 25/57 (43.9%) patients had disease progression (4 deaths, 11 hospitalizations for PAH, 14 with worsening in WHO FC, and 8 received PAH-specific combination treatment), with a 1-year survival rate of 93%. The following factors [odds ratio, (95% confidence interval)] were associated with disease progression: male gender [4.1 (1.2-14.1)], high Forced Vital Capacity (FVC) % predicted/ DLCO % predicted ratio [3.6 (1.2-10.7)], and high Borg dyspnoea index [1.7 (1.1-2.6)]. Low DLCO (% predicted) was also significantly associated with progression [area under the curve (95% CI) 0.8 (0.6-0.9)], but the relationship was not linear. Conclusions: More than 40% of early-diagnosed SSc-PAH patients in the DETECT cohort who were followed over time had disease progression during a rather short follow-up time, with male gender, functional capacity, and pulmonary function tests (low DLCO, high FVC%/DLCO % predicted ratio) at PAH diagnosis being associated with progression. This suggests that even mild and early detected PAH should be regarded as a high-risk complication of SSc, and every effort to make an early diagnosis is valuable. Acknowledgements: The authors thank all investigators and patients involved in
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